At least 5% of cancer diagnoses are attributed to a causal pathogenic or likely pathogenic
germline genetic variant (hereditary cancer syndrome—HCS). These individuals are …

Importance Personalized surveillance, prophylaxis, and cancer treatment options for
individuals with hereditary cancer predisposition are informed by results of germline genetic …

Purpose To determine the potential for detection of incidental germline cancer
predisposition mutations through cell-free DNA (cfDNA) analyses in patients who underwent …

Background We explored health professionals' views on the utility of circulating tumor DNA
(ctDNA) testing in hereditary cancer syndrome (HCS) management. Materials and Methods …

Pre-symptomatic screening of genetic alterations might help identify subpopulations of
individuals that could enter into early access prevention programs. Since liquid biopsy is …

Cancer is among the leading causes of death and disfigurement worldwide with an
estimated global incidence of 14 million and~ 8.2 million cancer-related deaths per annum …

Approximately 5%-10% of all cancer is due to hereditary causes. Over the last 2 decades,
the ability to detect genes responsible for hereditary cancers has dramatically improved, and …

An emerging role for DNA sequencing is to identify people at risk for an inherited cancer
syndrome in order to prevent or ameliorate the manifestation of symptoms. Two cancer …

Background Cell-free DNA (cf-DNA)-based liquid biopsy is emerging as a revolutionary new
method in individualized cancer treatment and prognosis monitoring, although detecting …

Cancer is one of the leading causes of death worldwide and remains a major public health
challenge. The introduction of more sensitive and powerful technologies has permitted the …